Scilex to Swap $200M in Stock for Bitcoin
Scilex plans to sell $200M in Semnur Pharma stock for Bitcoin, marking a bold crypto entry for the pharma industry.
- Scilex to exchange $200M in stock for Bitcoin.
- Pharma industry shows growing interest in crypto assets.
- Signals rising confidence in Bitcoin as a treasury reserve.
Pharma Giant Scilex Dives Into Bitcoin
In a surprising crossover between healthcare and crypto, Scilex Holding Company has announced plans to sell $200 million worth of Semnur Pharmaceuticals stock in exchange for $200 million in Bitcoin. The move marks one of the first major instances of a pharmaceutical company engaging in such a significant crypto transaction.
This bold decision highlights Bitcoin’s growing role not just as a speculative asset, but as a legitimate treasury reserve alternative. Scilex’s entry into Bitcoin could pave the way for more traditional, non-tech companies to consider diversifying their balance sheets with digital assets.
Bitcoin as a Treasury Asset Gains Ground
While corporate Bitcoin adoption has been mostly led by tech companies like MicroStrategy, this announcement signals a potential shift. The fact that a healthcare firm is willing to transact in and hold Bitcoin worth hundreds of millions suggests increasing institutional confidence in crypto.
This transaction doesn’t just involve buying Bitcoin on the open market—it’s a stock-for-Bitcoin deal, meaning the buyer sees Bitcoin as equally, if not more, valuable than equity in a growing pharma company. That’s a powerful statement.
A New Era for Corporate Crypto Strategy
Scilex’s decision reflects a changing mindset among corporations that see Bitcoin not just as a hedge against inflation, but also as a strategic long-term asset. As more sectors—including healthcare—begin to adopt Bitcoin, it strengthens the argument for crypto’s mainstream legitimacy.
If this trend continues, we may soon see Bitcoin appearing more frequently on corporate balance sheets well outside the tech and finance sectors.
Read Also:
- CZ Refutes FT’s YZiLabs Report as “False News”
- Polygon Faces Bug, Dogecoin ETF Moves, While BlockDAG’s Almost $410M Presale Redefines the Next Big Crypto Opportunity
- CFTC Explores Tokenized Collateral in Derivatives Market
- Bubblemaps Launches Intel Desk to Reward Scam Reports
- Missed Avalanche? Don’t Miss BullZilla – One of the Best Crypto Presales to Buy Now
